Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 2 February 2007. doi:10.1136/ard.2006.058644
Annals of the Rheumatic Diseases 2007;66:1276-1283
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2006.058644v1
ard.2006.058644v2
66/10/1276    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helmers, S. B.
Right arrow Articles by Lundberg, I. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helmers, S. B.
Right arrow Articles by Lundberg, I. E

EXTENDED REPORTS

Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies

Sevim Barbasso Helmers 1, Maryam Dastmalchi 1, Helene Alexanderson 2, Inger Nennesmo 3, Mona Esbjörnsson 4, Björn Lindvall 5, Ingrid E Lundberg 1

1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
2 Rheumatology Unit, Department of Medicine, Department of Physical Therapy, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
3 Department of Pathology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
4 Division of Clinical Physiology, Department of Medical Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
5 Neuromuscular Unit, Division of Neurology, Department of Clinical Neurosciences and Locomotion, University Hospital, Linköping; Muscular Centre, Department of Neurology, University Hospital, Örebro, Sweden

Correspondence to:
Sevim Barbasso Helmers, Karolinska University Hospital, Rheumatology Unit, CMM L8:04, SE-171 76 Stockholm, Sweden; Sevim.Barbasso{at}ki.se

Objectives: The study was conducted with the aim of achieving an improved understanding of the molecular mechanisms of high-dose intravenous immunoglobulin (IVIG) in inflammatory myopathies by investigating the effects on muscle function and immunological molecules in skeletal muscle of polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) patients.

Methods: Thirteen treatment-resistant patients, 6 PM, 4 DM, 2 IBM and 1 juvenile DM, were treated with 2 g/kg of IVIG, three times at monthly intervals. Functional Index in Myositis and serum creatinine kinase (CK) levels were determined, and muscle biopsies were performed before treatment and after the third IVIG infusion. Immunological molecules were also studied in biopsies taken 24–48 h after the first infusion.

Results: Improved muscle function was observed in three patients (1 PM, 1 DM and 1 IBM) and CK levels decreased in five. T cells, macrophages, major histocompatibility complex (MHC) class I antigen on muscle fibres, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression and membranolytic attack complex (MAC) deposits on capillaries were present to an equal degree in biopsies before and after IVIG treatment. No correlation between the clinical response and molecular changes was found.

Conclusions: The clinical effects of high-dose IVIG on muscle function in patients with refractory inflammatory active myositis did not correspond to effects on any of the investigated molecules in our study. T cells, macrophages, phenotypical changes in muscle fibres and endothelial cell activation were still present after treatment. These observations question a role for IVIG as an immune-modulating therapy in patients with inflammatory myopathies.


Abbreviations: CD, cluster of differentiation; CK, creatinine kinase; DM, dermatomyositis; FI, Functional Index in Myositis; IBM, inclusion body myositis; ICAM intercellular adhesion molecule, ; IL, interleukin; IVIG, intravenous immunoglobulin; MAC, membranolytic attack complex; MHC, major histocompatibility complex; PBMC, peripheral blood mononuclear cell; PM, polymyositis; VCAM, vascular cell adhesion molecule







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism